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Human soluble epoxide hydrolase (hsEH) is an enzyme responsible for the inactivation of
bioactive epoxy fatty acids, and its inhibition is emerging as a promising therapeutical
strategy to target hypertension, cardiovascular disease, pain and insulin sensitivity. Here, we
uncover the molecular bases of hsEH inhibition mediated by the endogenous 15-deoxy-Δ12,14-
Prostaglandin J2 (15d-PGJ2). Our data reveal a dual inhibitory mechanism, whereby hsEH can
be inhibited by reversible docking of 15d-PGJ2 in the catalytic pocket, as well as by covalent
locking of the same compound onto cysteine residues C423 and C522, remote to the active
site. Biophysical characterisations allied with in silico investigations indicate that the covalent
modiﬁcation of the reactive cysteines may be part of a hitherto undiscovered allosteric
regulatory mechanism of the enzyme. This study provides insights into the molecular modes
of inhibition of hsEH epoxy-hydrolytic activity and paves the way for the development of new
allosteric inhibitors.
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Human soluble epoxide hydrolase (hsEH) is a cytosolicenzyme which modulates the metabolism of bioactiveepoxy fatty acids (EpFAs), by converting them into their
corresponding vicinal diols1,2. In mammals, the enzyme is com-
posed of two structurally distinct domains connected by a
proline-rich linker3. Whilst the N-terminal domain exerts phos-
phatase activity on glycerophospoholipids and lysophosphatidic
acids4–6, the hydrolytic activity on EpFAs resides in the C-
terminal domain (CTD)7–9. This hydrolysis involves a SN2
nucleophilic attack by D335 on the least hindered carbon atom of
the epoxide, followed by water-mediated release of the alkyl-
enzyme intermediate, assisted by D496 and H524. Residues Y383
and Y466 provide support to catalysis through the establishment
of hydrogen bonds with the oxygen of the epoxy ring1. The
catalytic site of hsEH CTD has been described as an ‘L-shaped’
tunnel with both ends open to the solvent. The catalytic triad
(D335, D496 and H524) is located at the vertex of the ‘L’, edged
by two hydrophobic regions at both sides, namely the F267
Pocket and W334 Niche1,3. The EpFA substrates of hsEH CTD
are oxygenated derivatives of arachidonic, linoleic and α-linoleic
acids, which possess anti-inﬂammatory, antihyperalgesic and
vasoactive properties, and whose bioavailability has been linked to
cardiovascular, inﬂammatory and neurodegenerative diseases,
nociception and diabetes10–12. Of these substrates, the best
characterised are the epoxyeicosatrienoic acids (EETs)2,13,14,
which are endothelial-derived hyperpolarising factors able to
induce dilation of small-size arteries in vascular districts of kid-
neys, heart, lung and brain15–18. EETs exhibit other beneﬁcial
properties, such as anti-platelet aggregation, anti-inﬂammatory
effects, analgesic activity, apoptotic inhibition, vascular smooth
muscle cell anti-migratory action and cardio-protection16,19.
Given that hydrolysis of EETs to the corresponding diols, namely
dihydroxyeicosatrienoic acids, leads to largely inactive com-
pounds13, hsEH inhibition has emerged as a promising strategy to
enhance the bioavailability of EETs and reap their protective and
beneﬁcial effects. The search for hsEH inhibitors has been the
object of intense research for almost 30 years, leading to the
discovery of more than a thousand 1,3-disubstituted urea
antagonists, and related amides, carbamates, esters and carbo-
nates, able to inhibit hsEH20,21. Of the numerous compounds
developed, only few have reached clinical trials. The 12-(3-ada-
mantan-1-yl-ureido)-dodecanoic acid (AUDA), and its salts and
esters22, induced increased microvessel ﬂux in healthy and heart
failure human subjects, but its efﬁcacy at a systemic level was not
conclusively established23. The inhibitor AR9281 (1-adamanta-
nyl-3-(1-acetylpiperidin-4-yl) urea), reduced systolic blood pres-
sure in Angiotensin II-induced hypertensive mice, ameliorated
renal injury recovery and improved vascular function24. The
results of phase II clinical trials in patients with impaired glucose
tolerance and mild to moderate hypertension were however
inconclusive25,26. The compound GSK2256294 ((1R,3S)-(cis)-N-
{[4-cyano-2-(triﬂuoromethyl)phenyl]methyl}−3-{[4-methyl-6-
(methylamino)−1,3,5-triazin-2-yl]amino} cyclohexanecarbox-
amide) showed suppression of pulmonary inﬂammation in mice
exposed to cigarette smoke27, though the results from phase II
clinical trials with healthy volunteers, moderately obese smokers
and mild to moderate hypertensive patients are still pending28,29.
Given that no inhibitors characterised thus far has reached the
clinic, research into new hsEH antagonists remains active.
At endogenous level, sEH activity was thought to be exerted
largely by controlling protein expression level17. A breakthrough
in the ﬁeld was the discovery of a ﬁrst endogenous ligand, namely
15-deoxy-Δ12,14-Prostaglandin-J2 (15d-PGJ2), able to efﬁciently
modulate the activity of murine sEH30. 15d-PGJ2 is a product of
the arachidonic acid metabolism, generated in vitro by macro-
phages in response to inﬂammatory stimuli, and identiﬁed in vivo
in atherosclerotic plaques31, as well as in plasma during the
resolution phase of inﬂammation32,33. As an α/β-unsaturated
ketone electrophilic lipid, 15d-PGJ2 reacts in Michael additions
with cysteine residues of proteins34, including Kelch-like ECH-
associated protein 1 (Keap1)35, negative regulator of the nuclear
factor (erythroid-derived-2)-like 2 (Nrf2)36, peroxisome
proliferator-activated receptor gamma (PPARγ)35,37 and IκB
kinase (IKK)38,39, modulating their function and/or cellular
localisation. Charles et al.30 showed that 15d-PGJ2 induces
vasodilation of coronary vasculature of ex vivo perfused murine
hearts in a sEH-dependent manner. Given that a knock-in
C521S-sEH murine model showed resistance to 15d-PGJ2-
mediated vasodilation, the cysteine residue C521 (C522 in human
sequence numbering) was identiﬁed as the target of the Michael
addition by the electrophilic lipid. The molecular details of this
inhibition though remained unclear.
By using a combined biochemical and biophysical approach,
this study elucidates the mechanism of human sEH inhibition by
15d-PGJ2. hsEH was found to be covalently modiﬁed by 15d-
PGJ2 on two cysteine residues located outside the catalytic pocket,
one of which, C423, was to our knowledge discovered here for the
ﬁrst time, as it is not present in the murine ortholog. Most
importantly, we revealed that the covalent modiﬁcation of both
cysteines is accompanied by a conformational change of the
protein, thereby uncovering a hitherto unknown allosteric
mechanism of sEH inhibition. In addition to the allosteric con-
trol, our investigations show that 15d-PGJ2 is also able to inhibit
hsEH orthosterically, by interacting in a reversible non-covalent
manner with residues within the catalytic pocket. We therefore
propose a dual molecular model of 15d-PGJ2-mediated hsEH
inhibition, whereby the ligand can bind reversibly to hsEH
impeding the catalysis or adduct covalently the enzyme on
allosteric sites causing a conformational switch towards an
inactive state.
Results
15d-PGJ2 covalently modiﬁes two cysteines in hsEH CTD. To
investigate whether human sEH C-terminal Domain (hsEH CTD)
was covalently modiﬁed by the endogenous electrophilic lipid
15d-PGJ2, as reported for the murine ortholog30, electrospray
ionisation mass spectrometry (ESI-MS) experiments were per-
formed. Upon incubation of the human protein with the pros-
taglandin, three main peaks were detected (Fig. 1a): whilst one
matched the free protein molecular mass (39496.4 Da), the other
two showed a deconvoluted mass of 39810.3 and 40141.5 Da,
corresponding to the addition respectively of 312.1 and 645.1 Da.
These peaks were assigned to the covalent complexes formed
between hsEH CTD and 15d-PGJ2 molecules (316.4 Da), reveal-
ing that the protein is modiﬁed in vitro by either one or two units
of prostaglandin. No signal other than the apoprotein was
observed upon treatment with the reversible antagonist AUDA or
buffer alone. Liquid chromatography-tandem mass spectrometry
(LC-MS/MS) revealed two distinct sites of adduction for 15d-
PGJ2: C522 (Fig. 1b), located at the entrance of the F267 Pocket,
which corresponds to the murine counterpart C521 previously
identiﬁed;30 and C423 (Fig. 1c), a residue conserved only in
Primates (see below), located outside the active site, approxi-
mately 10 Å away from the edge of the F267 Pocket.
We next asked whether these two modiﬁcation sites on the
human sEH protein were equivalent. To evaluate the kinetics of
adduction on the two cysteines, we followed the appearance
overtime of the covalent adducts, comparing the behaviour of
wild-type hsEH CTD (WT) with that of single C423S and C522S
mutants, and C423S/C522S double mutant, replacing the reactive
cysteines with serines. The proteins incubated with 15d-PGJ2
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were analysed via HPLC reverse phase chromatography at various
time points (Fig. 1d, Supplementary Fig. 1). The UV elution
proﬁles for wild type (WT), C423S and C522S proteins showed
the presence of additional species that were retained in the reverse
phase column longer than apoproteins, which were assigned to
the covalently modiﬁed adducts. The lack of additional elution
peaks for the C423S/C522S mutant corroborated the identity of
the retained species and conﬁrmed that C423S and C522S are the
only targets of the Michael addition of 15d-PGJ2 to hsEH CTD.
Deconvolution of HPLC UV traces provided a measure for the
rate of adduct formation overtime, showing that the covalent
modiﬁcation of C423S and C522S occurs at different rates.
Interestingly, the C423S mutant experiences a considerably lower
adduction rate, indicating that C423 reacts with 15d-PGJ2 faster
than C522 (Fig. 1e).
15d-PGJ2 covalent adduction on C423 and C522 inhibits hsEH.
We interrogated the effect of Michael addition of 15d-PGJ2 to
C423 and C522 on hsEH CTD enzymatic activity. To purify the
covalent adducts, a bespoke separation strategy via Benzylthio-
Sepharose (BTS) afﬁnity chromatography resin was devised. BTS
is able to bind sEH through interactions between the enzyme’s
hydrophobic active site and benzylmercaptan moieties immobi-
lised onto Sepharose beads40,41. We hypothesised that the mod-
iﬁcation by 15d-PGJ2 might affect this interaction, possibly
through conformational effects (see below). Upon incubation
with 15d-PGJ2, a proportion of the WT, C423S and C522S
enzymes was indeed not retained by the BTS resin (Fig. 2a and
Supplementary Fig. 2). These ﬂow-through fractions were
unambiguously shown to contain prostaglandin-covalently
adducted proteins that failed to bind to the resin (Fig. 2b): their
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Fig. 1 Analysis of the covalent interaction between hsEH CTD and 15d-PGJ2. a ESI-MS experiments. Grey and black arrows indicate the free and covalently
modiﬁed hsEH CTD, respectively. The electrophilic carbon atoms of 15d-PGJ2 are indicated by asterisks. b LC-MS/MS evidence of C423 modiﬁcation. A
peptide with m/z 1154.092+ was assigned through the identiﬁcation of ions b2-b4, b6-b14 and y5-y17. The direct assignment of the modiﬁcation on both
b2-ions and y17-ions was strong evidence of modiﬁcation of C423. c LC-MS/MS evidence of C522 modiﬁcation. The peptide exhibited a m/z of 781.894+.
Its sequence was assigned through the detection of b3-b6, b8 and y2-y12 ions. The b6 ion modiﬁcation allowed the direct identiﬁcation of C522 adduction.
d HPLC separation of the covalent complexes. The traces were collected at three different time points, upon incubation of hsEH CTD and 15d-PGJ2. For
clarity, the chromatograms of the free proteins are reported in Supplementary Fig. 1. e 15d-PGJ2 rate of adduction. Rates were calculated from
deconvolution of the HLPC traces shown in d, as described in the Methods section. The mutant C423S showed a considerably lower rate of adduction to
C522, suggesting that the kinetics of modiﬁcation of the two residues are different. Data presented as average ± SEM of n= 4 WT, n= 3 C522, and n= 3
C423S. (Source data available in Supplementary Data 1)
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UV spectra in fact revealed a three-peak absorbance proﬁle, with
the expected aromatic amino acids absorbance at 280 nm and two
additional peaks at 250 and 330 nm, which matched the UV
spectrum of 15d-PGJ2 (Fig. 2b, Supplementary Fig. 3a). Not only
did this indicate a successful separation of prostaglandin-
modiﬁed proteins from the apoproteins, but also suggested that
in the covalently adducted species the active site of the enzyme is
somewhat altered, becoming unable to bind to the benzylmer-
captan compound.
The epoxy-hydrolytic activity of the puriﬁed hsEH proteins
covalently modiﬁed by 15d-PGJ2 was then evaluated using a
ﬂuorimetric-based assay42 (Fig. 2c, Supplementary Fig. 3b). These
experiments showed that the hsEH-15d-PGJ2 adducts experi-
enced a reduction of enzymatic activity when compared to
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apoproteins, with the single modiﬁcation of C423S and C522S
mutants inhibiting the enzyme to a lesser extent. This suggests
that the two cysteine residues are not equivalent in their ability to
impair enzyme activity when covalently modiﬁed, and that their
inhibitory effect is somewhat cumulative.
Although the covalent modiﬁcation on C522 and C423 inhibits
hsEH CTD, these cysteines are not located within the enzyme’s
catalytic pocket, nor are they involved in the mechanism of
epoxide hydrolysis. With C522 proximal to the entrance of the
catalytic tunnel on the F267 pocket, the covalently bound 15d-
PGJ2 moiety at this site may block access of the substrate to the
active pocket through steric hindrance. Nonetheless, this is not a
plausible explanation for C423, which is further away from the
catalytic crevice. To understand in greater depth the molecular
bases of this inhibitory mechanism, and prompted by the
behaviour of the 15d-PGJ2 adducts failing to bind the BTS
column, we next performed circular dichroism (CD) analysis
(Fig. 2d, Supplementary Fig. 3c). Far-UV CD proﬁles of WT-15d-
PGJ2, C423S-15d-PGJ2 and C522S-15d-PGJ2 covalent adducts
differed from the spectra of the respective apoproteins in overall
shape and molar ellipticities, thus reﬂecting changes in protein
secondary structure content upon covalent binding. Deconvolu-
tion analyses of CD data indicate that thiol modiﬁcation by 15d-
PGJ2 is accompanied by a decrease in α-helical and an increase of
β-strand content, and that double adduction of both cysteine
residues results in a somewhat cumulative effect (Table 1). This
indicates that the Michael addition of 15d-PGJ2 to both C423 and
C522 induces conformational changes in the enzyme that could
account for the impairment of hydrolytic activity. In other words,
an allosteric mechanism of inhibition43.
15d-PGJ2 reversibly binds the catalytic site of hsEH CTD. To
elucidate the basis of the 15d-PGJ2-mediated inhibitory
mechanism, we pursued a structural approach. First, we solved
the structure of apo hsEH CTD by X-ray crystallography, and our
results were found to be in excellent agreement with previously
deposited structures of the full-length enzyme9, with an RMSD of
0.257 Å on all CTD heavy atoms. The apoprotein crystallised in
space group I2, with two hsEH CTD molecules in the asymmetric
unit forming a homodimer (Fig. 3a, Supplementary Fig. 4;
Table 2). To obtain the structure of the covalent adducts, hsEH
CTD crystals were subjected to soaking with 15d-PGJ2 (Table 2).
Although one unit of the prostaglandin was found bound to each
monomer of hsEH CTD in the crystals, it was not covalently
attached to either C522 or C432, but instead was accommodated
in the F267 Pocket of the catalytic site (Fig. 3b, c). This structure
therefore depicts an orthosteric non-covalent interaction between
15d-PGJ2 and hsEH CTD. Superposition of the apo and holo
crystal structures gave an RMSD on all heavy atoms of 0.198 Å,
indicating a high similarity of the two structures. Minor changes
were observed in two regions proximal to the F267 Pocket
(Supplementary Fig. 5).
In the reversible non-covalent complex with 15d-PGJ2, the di-
unsaturated aliphatic chain and the ring of the ligand threaded
inside the F267 pocket, whilst the mono-unsaturated aliphatic
chain was found partially protruding outside the catalytic site
(Fig. 3d). The di-unsaturated aliphatic chain established van der
Waals contacts with protein residues of a hydrophobic surface
formed by F267, P268, Y383, L408, L417 and V498. The oxygen
of the 15d-PGJ2 ring engaged in a hydrogen bond with the
backbone nitrogen of F497. F497 also made van der Waals
contacts with the ligand benzylic moiety. Moreover, the hydroxyl
group of S412 and the backbone nitrogen of H524 were found at a
relatively short distance (around 3 Å) from the cyclopentenonyl
oxygen of 15d-PGJ2, suggesting that they may participate with
F497 in positioning the prostaglandin ring. Further van der Waals
Fig. 2 Analyses of 15d-PGJ2-hsEH CTD covalent complexes. a Puriﬁcation of 15d-PGJ2-hsEH CTD covalent adducts. SDS-PAGE analysis of the BTS
puriﬁcation of the proteins when incubated with either buffer (control) or 15d-PGJ2 (MWM, molecular weight marker; FT, ﬂow-through fraction; EL, elution
fraction). All the proteins bound to the BTS resin in the control treatment with buffer alone. Upon treatment with 15d-PGJ2, a fraction of the WT, C423S
and C522S enzymes was not retained by the resin and was collected in the ﬂow-through. The C423S/C522S mutant interacted with the BTS in all
conditions. Full uncropped gels are reported in Supplementary Fig. 2. b UV analyses of the covalent adducts. The ﬁgure reports the UV spectra of the BTS
fractions collected either in the ﬂow-through or in the elution fractions. The peaks at 250 and 330 nm conﬁrmed 15d-PGJ2 adduction to the proteins
collected in the BTS ﬂow-through (from panel a). c Comparative enzymatic activity analysis. The enzymatic activity of hsEH covalent adducts and
apoproteins were measured with a spectroﬂuorimetric assays. The comparison showed a signiﬁcant reduction in hydrolytic activity for the covalent
complexes (ND, non-determined; as the C423S/C522S did not generate any adduct). The asterisks refer to one-tailed homoscedastic t-test (apoprotein vs.
adducts), and the signiﬁcance is indicated as follows: *0.05 < p≤ 0.005, **0.005 < p≤ 0.0005, ***p < 0.0005. Data presented as average ± SEM of n= 6
WT, n= 6 C522, n= 5 C423S, and n= 5 C423S/C522S. (Source data available in Supplementary Data 2). d CD analyses. Comparison of the CD spectra of
the apoproteins (WT, C423S and C522S) and the corresponding 15d-PGJ2 covalent adducts revealed a conformational rearrangement upon 15d-PGJ2
modiﬁcation (see Table 1). Spectroscopic and enzymatic analyses of the other fractions collected in the puriﬁcations are reported in the Supplementary
Fig. 3
Table 1 CD data deconvolution. Secondary structure content analyses indicate a decrease in α-helical and an increase in β-strand
content upon modiﬁcation
α-helices (%) β-strands (%) Turns (%) Unordered (%)
WT
Adducts 22.5 35.5 21.9 29.6
Apoprotein 33.4 17.3 22.0 29.5
C423S
Adduct 22.5 24.4 22.7 27.3
Apoprotein 29.2 18.2 22.4 30.6
C522S
Adduct 26.5 19.6 23.0 29.1
Apoprotein 32.0 17.5 21.2 29.3
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contacts were established between Cβ and Cγ of H524 and 15d-
PGJ2 di-unsaturated aliphatic chain, S412 and the cyclopenteno-
nyl ring of the prostaglandin, and S415, L417 and M419 and the
mono-unsaturated aliphatic chain of the ligand.
The ﬁnding that 15d-PGJ2 was able to bind reversibly in the
enzyme catalytic pocket was not anticipated, thus saturation-
transfer difference NMR (STD-NMR) experiments were per-
formed to support the crystallographic data. The 1H-NMR
spectrum of the 15d-PGJ2 (Fig. 4a) was assigned from deposited
chemical shift data44 and a 1H-NMR spectrum of hsEH CTD was
recorded (Supplementary Fig. 6a) as control. The off-resonance
(I0) and on-resonance (ISAT) spectra (Fig. 4b) were acquired on
the hsEH CTD and 15d-PGJ2 mixture, in parallel with a control
experiment performed by irradiating a solution of prostaglandin
alone (Supplementary Fig. 6b). Spectra subtraction of the protein-
ligand mixture revealed saturation of several protons of the
prostaglandin, and their STD ampliﬁcation factor (ASTD) values
were plotted against the irradiation time, showing the expected
hyperbolic proﬁle (Fig. 4c). Epitope mapping indicates a stronger
interaction of the di-unsaturated aliphatic chain of 15d-PGJ2 with
hsEH CTD in solution (Fig. 4d), in agreement with the
crystallographic structure. Overall, the combined crystallography
and solution approach revealed that 15d-PGJ2 is able to bind
non-covalently within the catalytic pocket of hsEH CTD.
Next, we sought to examine the impact of 15d-PGJ2 reversible
interaction on hsEH enzymatic activity. To assess solely the
reversible orthosteric effect of the ligand, the C423S/C522S
mutant protein was used in spectroﬂuorimetric assays, revealing a
half maximal inhibitory concentration (IC50) of 30.03 ± 0.61 µM
and an inhibitory constant (Ki) of 8.56 ± 0.17 µM (Fig. 5a and
Supplementary Fig. 7a). Minimising the incubation time and
therefore the formation of covalent adduct(s), the IC50 and Ki of
the 15d-PGJ2 for the WT CTD were also measured, as a control
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Fig. 3 X-ray crystallographic structure of the 15d-PGJ2-hsEH CTD complex.
a Crystallographic symmetry. The crystallographic homodimer is
represented as a cartoon model (chain A and B in light blue and salmon red
respectively), with the ‘L’-shaped catalytic site in mesh. b Electron density
of the 15d-PGJ2 bound to hsEH CTD. The 2Fc-Fo map was contoured at
1 sigma. c 15d-PGJ2 binding site. The ‘L-shaped’ catalytic site of hsEH CTD
is represented with a three-colours code: the F267 Pocket in magenta; the
W336 Niche in cyan; the ‘L’ vertex formed by the catalytic D335 and the
epoxide positioners Y363 and Y466 are represented in blue. d Overall 15d-
PGJ2 interaction with hsEH CTD. The amino acids involved in van der
Waals interaction are depicted in brown, while those forming hydrogen
bonds with 15d-PGJ2 are in dark cyan. C423 and C522 are highlighted in
orange, and the reactive electrophilic C13 and C15 atoms of the ligand are
indicated by asterisks
Table 2 Data collection statistics for hsEH CTD in apo-state
and complexed to 15d-PGJ2
Apo hsEH CTD Complexed
hsEH CTD
Data collection
Space group I 1 2 1 I 1 2 1
Cell dimensions
a, b, c (Å) 88.22,
80.14, 104.70
89.49,
79.99, 104.54
α, β, γ (°) 90.00,
95.39, 90.00
90.00,
96.78, 90.00
Resolution (Å) 29.60–2.60
(2.72–2.60)
29.73–2.00
(2.05–2.00)
Rsym (%) 9.1 (66.4) 9.6 (63.5)
I/σI 5.7 (2.1) 10.2 (2.3)
Completeness (%) 99.9 (100.0) 99.2 (91.6)
Redundancy 5.1 (5.0) 5.0 (4.6)
Reﬁnement
Resolution (Å) 2.60 2.0
No. reﬂections (observed/
unique)
114,202/22,492 244,141/48,933
Rwork/Rfree (%) 24.6/27.7 17.4/21.9
No. atoms
Protein 5086 5103
Ligand/ion N/A 46
Water 13 226
B-factors (Å2)
Protein 45.5 34.0
Ligand/ion N/A 65.3
R.m.s. deviations
Bond lengths (Å) 0.0104 0.0168
Bond angles (°) 1.4487 2.0545
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(Fig. 5b and Supplementary Fig. 7b). These values (IC50 45.69 ±
5.40 µM; Ki 13.03 ± 1.54 µM) were largely in agreement with the
ones obtained for the C423S/C522S mutant, indicating that both
experiments are describing the same molecular process. Based on
these data, we concluded that 15d-PGJ2 can inhibit hsEH both in
the reversible and in the covalent state, in other words both
orthosterically and allosterically.
15d-PGJ2 adduction destabilises the hsEH CTD active site.
Whereas the orthosteric inhibition by 15d-PGJ2 was characterised
at the atomic level by the crystal structure described above, a
molecular description was lacking for the allosteric effect medi-
ated by covalent modiﬁcations at C522 and C423. Despite
numerous attempts, no satisfactory X-ray crystallography dif-
fraction data for the covalent adducts were obtained. In parallel,
we undertook an in silico approach to predict the conformational
effects of prostaglandin addition at the two cysteine sites. Swiss-
Dock identiﬁed several putative binding poses of 15d-PGJ2 sur-
rounding C423 and C522. Those with the shortest distance
between the ligand electrophilic carbon atoms and the
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nucleophilic thiols of the reactive cysteine residues were selected
(Fig. 6a) and used as input for AlloSigMA, a structure-based
statistical mechanical model tool which measures difference in
conﬁgurational work exerted by binding of an allosteric ligand on
a per-residue allosteric free energy (Δgi) decomposition, using
normal mode analyses45. Increased (positive sign) and decrease
(negative sign) Δgi correspond respectively to predicted local
destabilisation and stabilisation of the conﬁgurational energy
(Δgi) associated with the calculated modes of the ‘rigidiﬁed’
(perturbed) binding site. When the C423 site was analysed, a
decrease of Δgi was shown for Y383, one of the two epoxide-
positioners involved in the hydrolysis (Fig. 6b and Supplementary
Fig. 8). Conversely, the catalytic residue D335 exhibited a con-
siderable increase in Δgi, suggesting that 15d-PGJ2 binding may
induce the repositioning of this key residue impairing the cata-
lysis. Moreover, a milder increase in Δgi was observed for the
other epoxide positioner Y466, as well as for some of the residues
of the W336 niche, suggesting an induced conformational change
of this side of the binding pocket upon perturbation of the
C423 site. When the C522 site was investigated, the entire cata-
lytic triad (D335, D496, H524) showed a decrease in Δgi, whilst
the two epoxide positioners (Y383, Y466) and the residues from
both W336 niche (W336, M469) and F267 Pocket (F267, L408,
M419, V498) exhibited a Δgi increase (Fig. 6c). This would sug-
gest that the ligand binding on the C522 site induces a stabili-
sation of the catalytic triad, inducing a large conformational
change of the binding pocket, and possibly leading to transition
towards an inactive state. When both C423 and C522 sites were
analysed in conjunction, an enhanced stabilisation of the catalytic
triad was associated with a large-amplitude motion of the binding
pocket, as showed by the greater destabilisation of the epoxide
positioners, as well as the W336 niche and F267 Pocket (Fig. 6d).
Altogether, our in silico analysis supports an allosteric regulation
of 15d-PGJ2 mediated by its covalent binding to the two reactive
cysteine residues C423 and C522.
Discussion
Previous studies proposed that 15d-PGJ2 inhibits murine sEH by
covalent modiﬁcation of C52130. In this study, we revealed that
15d-PGJ2 exerts inhibition of the human sEH ortholog by binding
both non-covalently in the catalytic pocket and covalently to
reactive cysteine residues, one of which, namely C423, was
not characterised in earlier work. Our X-ray crystallographic
structure places 15d-PGJ2 in the active site, resulting in reversible
enzyme inhibition with a Ki in the low micromolar range. The
position of 15d-PGJ2 in the outer region of the F267 Pocket
suggests that inhibition is achieved largely by impairment of
substrate binding to the active site, although contacts between
the ligand and the catalytic residue H524, as well as the
epoxy-positioner Y383, do not exclude the possibility of a reduced
availability of crucial amino acids involved in the hydrolytic
reaction. In addition to this reversible orthosteric inhibition, our
studies corroborated that hsEH activity is hindered by covalent
modiﬁcation of reactive cysteine residues, although contrary to
the murine enzyme30, two residues were unveiled in the human
ortholog by our investigations, namely C423 and C522. We
demonstrated that, although the covalent modiﬁcation of a single
cysteine site results in inhibition, the adduction to both residues
leads to a greater decrease in the enzymatic activity of hsEH CTD.
A major outcome of this work is that C423 was discovered as a
modiﬁcation site in human. Interestingly, this residue is con-
served only in primates, suggesting that the modulation of soluble
epoxide hydrolase differs within the tetrapod lineage (Fig. 7a).
Intriguingly, our data appear to indicate that C423 is modiﬁed by
15d-PGJ2 at faster rate of adduction than C522 and that this leads
to a greater level of enzyme inhibition, although the relative
importance of these two residues in an in vivo setting remains to
be established.
Taken together, our data suggest a dual mode of inhibition of
hsEH CTD by 15d-PGJ2 (Fig. 7b), that could be modelled as an
extension of the ‘dock-and-lock’ mechanism previously described
for another 15d-PGJ2 target, namely PPARγ46. This model
envisages that the reversible ‘docking’ of 15d-PGJ2 in the catalytic
pocket would be followed by the covalent ‘locking’ on the two
reactive cysteines C423 and C522. Both states lead to reduction of
enzymatic activity, though the fast reversible interaction may
facilitate and drive the slower covalent addition (reversible-driven
covalent addition), which by its nature would have a prolonged
and more potent effect overtime. The position of C423 and
especially C522 around the catalytic pocket may support this
hypothesis. In this context it may be plausible that the docking-
to-locking (or reversible-to-covalent) switch is regulated by the
oxidation redox status of the reactive cysteine residues and other
environmental clues that may change the reactivity and/or
availability of their thiol groups. Nonetheless, a direct and con-
sequential link between the reversible and irreversible mode of
inhibition of 15d-PGJ2 may not necessarily exist, providing
instead alternative ways to inhibit the enzyme.
In our X-ray crystallographic structure, the prostaglandin was
found inside the active site, speciﬁcally occupying the F267
Pocket of the L-shaped catalytic tunnel. The majority of sEH
orthosteric inhibitors are 1,3-disubstituted urea antagonists, and
variations thereof, able to position themselves in and around the
vertex region, impeding substrate access to the catalytic triad20,47
(Fig. 7c). Although numerous sEH antagonist were found to
target the F267 region20,48,49, we identiﬁed a continuous binding
surface for 15d-PGJ2, involving residues S412, S415, L417 and
M419. These unique binding features allow the delineation of a
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novel interacting surface, at the very entrance of the catalytic site
(Fig. 7c), which could potentially be exploited as an anchoring
region in the design of new orthosteric hsEH inhibitors with
different chemical scaffolds. More importantly though, because of
its ability to undergo Michael addition with allosteric residues
C522 and C423, 15d-PGJ2 could represent a putative lead
molecule for the development of new covalent allosteric drugs for
hsEH, whose advantages include higher speciﬁcity, increased
biochemical efﬁcacy, a preference for shallow binding pockets,
lower toxicity and lower administration doses, high enough for
the drug molecule to reach each target protein and persist until
the body has produced more protein50,51. Furthermore, the
prospect of allosteric inhibition would potentially circumvent the
historical drawbacks associated with orthosteric inhibitors, none
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of which has succeeded in clinical trials, despite intense and
sustained efforts20,21,26,28,29.
In this study we provide new critical evidence on the
mechanism by which the covalent modiﬁcation of 15d-PGJ2 on
C522 and C423 inhibits hsEH CTD. Notably, these cysteine
residues are not located within the active site, nor are in any way
involved in the epoxide hydrolysis, thereby indicating an allos-
teric modulation of the enzyme via post-translation modiﬁcation.
Our CD studies show that 15d-PGJ2 adduction on both C423 and
C522 is accompanied by conformational changes in hsEH CTD,
possibly affecting the active site. This would in turn disrupt
substrate accessibility and/or render substrate binding less
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favourable thermodynamically. Consistent with this, upon 15d-
PGJ2 covalent modiﬁcation the enzyme was no longer capable of
binding the high afﬁnity benzylmercaptan compound immobi-
lised onto the BTS resin. The biophysical characterisation was
backed up by in silico studies that were able to predict allosteric
communication between the C423 and C522 binding surfaces and
the catalytic site, particularly affecting the conformation of the
two epoxide positioners and various other residues in both W336
niche and F267 Pocket. A picture is emerging in which the
covalent modiﬁcation of these cysteines remote from the catalytic
site elicits conformational and dynamics changes of the hsEH
CTD towards an inactive state, although the detailed mode of
regulation awaits structure determination of C522/C423-adduc-
ted covalent complex(es). Notably, in the case of C522, its loca-
tion in the vicinity of the entrance of the catalytic tunnel does not
rule out the possibility that the allosteric regulation may be
coupled with a steric hindrance effect also contributing to inhi-
bition. Given its location remote from the catalytic pocket, the
same cannot be argued for C423 (Fig. 7c).
From a physiological perspective, it could be envisaged that
15d-PGJ2 may regulate hsEH enzyme activity in various tissues
where the prostaglandin and the hydrolase co-localise, such as
astrocytes, macrophages, and small size arteries14,17,34. Interest-
ingly, 15d-PGJ2 possesses anti-inﬂammatory activities31,34,52 and
its production increases in response to inﬂammatory stimuli33.
Although further studies are needed to correlate the levels of 15d-
PGJ2 production and hsEH activity, one may speculate that
enhanced prostaglandin levels may imply a greater inhibition of
sEH, which in turn would augment the bioavailability of EETs
and other epoxy-fatty acids with anti-inﬂammatory properties,
possibly contributing synergically to the resolution of the
inﬂammation and inducing cardio- and neuroprotection16,53,54.
In conclusion, our research unveiled that hsEH CTD under-
goes a dual mechanism of inhibition with the endogenous 15d-
PGJ2, mediated by covalent and non-covalent interactions. The
latter reversible interaction uncovered a putative new orthosteric
binding surface to be exploited for the design of new drugs.
Although the molecular details of hsEH structural perturbation
upon covalent adduction are yet to be fully understood, our data
taken together strongly support a hitherto undiscovered allosteric
mechanism of hsEH regulation. Altogether, this study provides
new insight in the regulatory mechanism of the epoxy-hydrolytic
activity of hsEH and paves the way for new modes of sEH
inhibition for improving cardiovascular health, inﬂammation and
diabetes.
Methods
Plasmid construction and site directed mutagenesis. The EPHX2 (T230-M555
—hsEH CTD) cDNA was cloned in the bacterial expression vector pET3a, as
described previously41. Single mutants C423S and C522S were generated with the
Q5® Site-Directed Mutagenesis Kit (NEB). The double mutant C423S/C522S
(C423S/C522S) was produced through two subsequent cycles of mutagenesis using
the same kit. The mutagenic primers (Sigma), were designed with the NEB changer
webtool according to the kit speciﬁcations (C423S_R: 5′GCATAAAGTCAGTGAA
GCGGG3′; C423S_F: 5′ATGGATAAAACACTCTCATCG3′; C522S_R: 5′CATTG
AGGACAGTGGGCACTG3′; C522S_F: 5′TGTCCCCTTTTCAGGTGG3′). Suc-
cessful mutagenesis was conﬁrmed by sequencing (Euroﬁns MWG).
Protein expression and puriﬁcation. The hsEH CTD and its mutants were
expressed in Ros2TM(DE3) (EMD Millipore) and puriﬁed as described previously
for WT41.
Electrospray ionisation mass-spectrometry (ESI-MS). hsEH CTD protein
sample was dialysed overnight at 4 °C in 25 mM HEPES, 300 mM NaCl, 10%
glycerol, pH 7.4, 10 μM tris(2-carboxyethyl)phosphine (TCEP) (reaction buffer).
The protein was incubated overnight at 4 °C 1:8 v/v (molar ratio) with 15d-PGJ2
(BertinPharma—dissolved in PBS), AUDA (Sigma—dissolved in PBS), and PBS as
control. At the end of the incubation period, the reaction was quenched by adding
5 mM DTT, and excess ligand was removed by buffer exchange on an Amicon
Ultra-0.5 mL centrifugal Filter (Merck) at 10,000×g and 4 °C. The samples were
diluted in 0.1% formic acid at a ﬁnal concentration of 60 μg mL−1, and injected
directly into the maXis instrument (Bruker) via a motorised pump with at a ﬂow
rate of 10–50 μLmin−1. The spectra were recorded for 3–30 min at a spectral rate
of 1 Hz, with an end plate offset of −500 V, a capillary voltage of −4500 V, a
nebuliser pressure of 3.0 bar, and a tuned ISCID energy between 80 and 110 eV.
The spectra obtained were deconvoluted using microTOF software (Bruker), per-
forming a maximum entropy analysis.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS). Fifty
microgram of hsEH CTD, incubated overnight at 4 °C with 15d-PGJ2 (1:8 v/v
protein-to-ligand molar ratio), was separated by SDS-PAGE on a 20% bis-
acrylamide gel, for 30 min at 100 V (according to Laemmli protocol55). The protein
bands were cut in discrete pieces and digested overnight with 5 μg of trypsin
(Sigma-Aldrich) at room temperature, after an initial incubation at 37 °C for 2 h.
Peptides were extracted from the gel by a series of acetonitrile and aqueous washes,
and the extract was lyophilised and resuspended in 10 μL of 50 mM ammonium
bicarbonate. Chromatographic separation of the peptides was performed using an
EASY NanoLC system (ThermoFisher Scientiﬁc), by reversed phase chromato-
graphy on a 75 μm C18 column, using a three-step linear gradient of acetonitrile in
0.1% formic acid. The gradient was delivered to elute the peptides at a ﬂow rate of
300 nL min−1 over 60 min. The eluate was ionised by electrospray ionisation using
an Orbitrap Velos Pro (ThermoFisher Scientiﬁc), operating under Xcalibur v2.2.
The instrument was programmed to acquire in automated data-dependent
switching mode, selecting precursor ions based on their intensity for sequencing by
collision-induced fragmentation using a Top20 CID method. MS/MS analyses were
conducted using collision energy proﬁles that were chosen based on the mass-to-
charge ratio (m/z) and the charge state of the peptide. Raw mass spectrometry data
were processed into peak list ﬁles using Proteome Discoverer (ThermoScientiﬁc;
v1.4). Processed raw data were analysed using the Mascot 2.2.06 (Matrix Science)
search algorithm against ‘All Taxonomy' in the Uniprot database and an in-house
database containing the protein sequence of interest, assuming the digestion
enzyme trypsin. Mascot was searched with a fragment ion mass tolerance of 0.80
Da and a parent ion tolerance of 20 ppm. 15d-PGJ2 modiﬁcation of cysteine
residues was speciﬁed in Mascot as variable modiﬁcations. Scaffold 4.7.5 (Proteome
Software Inc) was used to validate MS/MS based peptide and protein identiﬁca-
tions. High stringency ﬁlters of 95% conﬁdence interval (CI) for minimum protein
and 0% CI for peptide values was applied. A 95% probability CI in the MOWSE
scoring algorithm in Mascot was applied. Protein probabilities were assigned by the
Protein Prophet algorithm56. The analysis yielded 42 unique peptide fragments
(88% sequence coverage), of which two were unambiguously modiﬁed by 15d-
PGJ2.
High-pressure liquid chromatography (HPLC) analyses. hsEH CTD WT,
C423S, C522S and C423S/C522S proteins were dialysed overnight at 4 °C in
reaction buffer (see ESI-MS section), and then incubated at 4 °C 1:8 v/v (molar
ratio) with 15d-PGJ2 (dissolved in PBS). After 30 min, 2.5 h or 20 h, the reaction
was quenched by adding 5 mM DTT and immediately ﬂash-frozen in liquid
nitrogen. 2.5 μg of the protein samples were mixed with 10 mM TRIS-HCl pH 7.5,
to be loaded, using an Agilent 1200 HPLC system, on a reversed phase column
(ACE 5 C18–300, 250 × 4.6 mm). The species were eluted with a 48–60% gradient
of acetonitrile and 0.1% TFA, over 12 min at 1 mLmin−1. The traces obtained were
deconvoluted with Fityk software57 and the peaks integrated with a Pearson VII
function. The areas under the peaks were used to back calculate the amount of
adduct observed at each time point of the reaction and extrapolate the rate of
adduction.
Fig. 7 Analysis of sEH binding modes for 15d-PGJ2. a Protein sequence alignment. Alignment of sEH amino acid sequences of different species, highlighting
C423 and C522 in the top and bottom panel respectively. The red boxes highlight the reactive cysteine residues. The secondary structure reported above
the alignments refers to the human apo sEH structure. The histograms represent the conservation score calculated by Jalview71 (*full conservation, +: full
properties conservation). b Proposed dock-and-lock binding mechanism. In a ﬁrst fast step, 15d-PGJ2 docks non-covalently in the hsEH CTD binding site
(docked state). This is followed by the formation of a covalent complex (locked state), and this step is characterised by a slower kinetics. c 15d-PGJ2
binding position compared to previously characterised orthosteric inhibitors 4XH, CDU, S0J. The surfaces represent the Phe267 Pocket (magenta), the
Vertex (blue) and the Trp334 Niche (cyan), while residues C423 and C522 are reported in orange. The superposition herein reported was performed using
PDBs 1EK247, 3WKC72 and 5AI649
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Puriﬁcation of covalent adducts. To purify the covalent adducts, we designed a
tailored Benzylthio-Sepharose (BTS) afﬁnity chromatography protocol. Apo-hsEH
CTD binds BTS via interactions between the enzyme’s hydrophobic binding pocket
and benzylmercaptan moieties immobilised onto Sepharose beads40,41, whilst
covalently adducted counterparts do not interact with the resin and were collected
in the column ﬂow-through fractions. 15d-PGJ2-hsEH CTD covalent adducts were
prepared as follows. 0.5 mg of WT, C423S, C522S, and C423S/C522S proteins were
dialysed overnight at 4 °C in 25 mM 3-(N-morpholino)propanesulfonic acid
(MOPS) pH 7.4, 75 mM NaCl, 5% glycerol, 10 μM TCEP (binding buffer), and then
incubated at 4 °C 1:8 v/v (molar ratio) with 15d-PGJ2 (dissolved in PBS) or binding
buffer (as control). After overnight incubation, the mixtures were loaded onto 500
μL of BTS resin in gravity columns (prepared in-house41), previously equilibrated
in binding buffer. After 15 min incubation at room temperature, the ﬂow-through
was collected and the resin washed ﬁve times with 500 μL of binding buffer. Five
hundred microliter of elution buffer (binding buffer containing 1 mM 2-benzoyl-3-
phenyloxirane) were added onto the resin to incubate for 15 min before elution.
The protein samples were eluted with 5 × 500 μL elution buffer and collected. SDS-
PAGE analyses were carried out to identify the proteins in the fractions. The ﬂow-
through and elution fractions containing protein were pooled together and dialysed
overnight at 4 °C in 20 mM TRIS-HCl pH 7.4, 100 mM NaCl, 2% glycerol, 10 μM
TCEP, concentrated to 0.5 mg mL−1 and ﬂash frozen in liquid nitrogen.
hsEH CTD enzymatic activity measurements. The activity of the isolated pro-
teins was measured using a spectroﬂuorometric method which monitors hsEH-
mediated hydrolysis of the synthetic substrate 3-phenyl-cyano(6-methoxy-2-
naphthalenyl)methyl ester-2-oxiraneacetic acid (PHOME), through the detection
of the ﬁnal ﬂuorescent product 6-methoxy-2-naphthaldehyde (6M2N)58. Protein
samples were diluted to a ﬁnal concentration of 50 nM in 25 mM TRIS-HCl pH 7.4
in a black 96-well polystyrene microtiter plate (Thermo Scientiﬁc). A fresh 0.4 mM
solution of the synthetic substrate PHOME was prepared in DMSO and diluted
1:40 v/v in the 96-well plate. The measurements of ﬂuorescence units (RFUs)
generated by the hsEH CTD-mediated hydrolysis of PHOME were carried out in
quadruplicate for 20 min using a POLARstar Omega (BMG Labtech), with the
following setup: excitation/emission wavelengths 330/460 nm, gain 750, detection
every 45 s, and temperature at 30 °C. Each sample of three different protein pre-
parations was tested in triplicate. Quantiﬁcation of the epoxy-hydrolytic rate was
carried out using a conversion curve reporting the ﬂuorescence of 6M2N, as a
function of the ﬂuorophore concentration, as described previously41.
Ultraviolet–visible (UV) and circular dichroism (CD) spectroscopy. UV and
CD spectra were acquired at 25 °C on an Applied Photophysics Chirascan Plus
spectrometer (Leatherhead, UK). 10 mm (500–220 nm) and 0.5 mm (260–190 nm)
Quartz Suprasil rectangular cells (Starna Scientiﬁc Ltd) were employed. The
instrument was ﬂushed continuously with pure evaporated nitrogen throughout
the experiment. The following parameters were set: 2 nm spectral bandwidth, 1 nm
step size, and 1 s instrument time per point. Light-scattering adjustment and buffer
subtraction were applied to the UV spectra of each sample, using the Chirascan
Pro-Data Software (APL). UV and CD spectra of the covalent adducts were
recorded at a ﬁnal concentration of 0.15 mgmL−1 (calculated using the A280nm
value obtained upon light-scattering correction and the extinction coefﬁcient
computed using the ProtParam tool within ExPASy Portal59). The far-UV CD
spectra were smoothed with a window factor of 4 using the Savitzky-Golay method
for better presentation, then corrected for concentration and pathlength, and
expressed in terms of mean residue ellipticity (MRE). Protein secondary structure
content was assessed using the SELCON 3 algorithm (data set 4), embedded in the
Dichroweb webtool60.
X-ray crystallography. Recombinant hsEH CTD was crystallised by vapour dif-
fusion, in sitting drops containing 100 nL of protein solution (hsEH CTD con-
centration 10 mgmL−1, in 50 mM HEPES, 300 mM NaCl, 10% glycerol, 3 mM
DTT, pH 7.4), and 200 nL of precipitation buffer (22.5% PEG 3350, 0.2 M malic
acid), equilibrated against a 20 μL reservoir of precipitant buffer at 4 °C. After
~5 days, cubic crystals of around 30 × 30 × 30 μm were obtained. Following soaking
in precipitant buffer containing 25% ethylene glycol and ﬂash cooling in liquid
nitrogen, crystals yielded diffraction data to 2.6 Å at the Diamond Light Source,
Didcot, UK. The diffraction data were reduced, scaled, and merged using
XIA2 software61. The crystals belonged to space group I121, with unit cell para-
meters a= 88.22, b= 80.14, and c= 104.70 Å. Crystals were then soaked in pre-
cipitation buffer containing 10 mM 15d-PGJ2 (Cayman Chemical, USA), incubated
for 15 min, cryoprotected with 25% ethylene glycol and ﬂash frozen in liquid
nitrogen. Diffraction yielded a resolution of 2 Å. Upon reduction, merging, and
scaling with XIA2 software61, the structure was solved by molecular replacement in
PHENIX62, using the deposited PDB ﬁle 3ANS63. The density map was explored
and built in COOT64, and the structure was reﬁned iteratively by automatic
structure reﬁnement using the software Refmac5 within CCP4 suite65. The 15d-
PGJ2 molecule was added into the ﬁnal stages of reﬁnement. Data reduction and
reﬁnement statistics are reported in Table 2.
Half maximal inhibitory concentration (IC50) measurements. The inhibitory
potency of 15d-PGJ2 was measured using an end-point adaptation of the PHOME
spectroﬂuorometric method described above. Recombinant hsEH CTD WT and
C423S/C522S were reduced with 10 µM TCEP on ice for 15 min, then diluted in a
96-well polystyrene microtiter plate in freshly prepared 25 mM TRIS-HCl pH 7.4
to a ﬁnal concentration of 15 nM. The proteins were then incubated at room
temperature for 10 min with 15d-PGJ2 (diluted 1:40 v/v to obtain increasing con-
centration between 0.1 and 250 μM). A fresh 0.4 mM solution of PHOME was
prepared in DMSO and diluted 1:40 v/v in the 96-well plate. A POLARstar Omega
(BMG Labtech) was used to measure the relative ﬂuorescence units (RFUs) for 20
min, using the same setting as above. Measurements were performed in four
replicates, for a total of four technical repeats. The readouts at 12 min reaction
times were corrected for the background signal generated by the PHOME auto-
hydrolysis, converted into nmol of 6M2N (6-methoxy-2-naphthaldeyde) and
plotted as percentage of activity against the Log10 of 15d-PJG2 concentration58. The
data points were ﬁtted with ‘log(inhibitor) vs. response—variable slope' in
GraphPad, and further considered only if R2 was ≥0.9. Inhibitory constants (Ki)
values were calculated using the Cheng-Prusoff equation66.
Saturation-transfer difference NMR (STD-NMR). STD-NMR is a technique for
the detection of reversible binding interactions between small molecule ligands and
macromolecular interactors in solution67. NMR spectra were recorded on a Bruker
AVANCE-500 NMR spectrometer (Bruker). Both hsEH CTD and 15d-PGJ2
samples were prepared in 50 mM HEPES, 300 mM NaCl, 10% glycerol, 0.1 mM
TCEP, pH 7.4, 10% D2O. After recording the 1H-NMR-I0 spectra of both hsEH
CTD (10 μM) and 15d-PGJ2 (1000 μM), STD-NMR experiments were performed at
293.15 K, mixing protein and ligand at a 1/100 v/v molar ratio, with the pulse
sequence stddiffesgp.3, using a train of Gaussian pulses of 50 ms duration at a
power level of 86 Hz, spaced by a delay of 1 ms. The irradiation power of the
selective pulses was set to (γ/2π)B1= 86 Hz. Selective pre-saturation of the protein
was achieved by a train of Gauss-shaped pulses of 50 ms length each, separated by a
1 ms delay. Irradiation was performed at −0.55 ppm (and −30 ppm as reference)
for a total saturation time spanning between 0.5 and 6 s. The subtraction of the
saturated spectra from the reference spectra was performed using TopSpin3.2, after
identical processing and phasing. Control experiments were performed by irra-
diating the ligand in isolation (same experimental setting as for above): no STD
signal was detected, conﬁrming that the saturation observed in presence of the
protein was due to the interaction between hsEH CTD and 15d-PGJ2. The STD
effect was quantiﬁed in terms of ampliﬁcation factor (ASTD), calculated with the
following equation:
ASTD¼
ISTD
I0
 ½15dPGJ2½hsEH CTD
where ISTD/I0 corresponds to the ratio between STD (ISTD) and off-resonance (I0)
signals, and [15d-PGJ2]/[hsEH CTD] is the ligand-to-protein molar ratio68. Per-
centage ASTD values were calculated by normalising for the greatest ASTD value
observed (C20) and used to model the hsEH CTD—15d-PGJ2 epitope mapping
interaction68.
Microscale thermophoresis. hsEH CTD protein was dialysed in 25 mM HEPES,
pH 7.4, 300 mM NaCl, 2% glycerol, 10 µM TCEP and labelled in dark with the
amino-reactive blue dye, following the Monolith NT Protein Labelling kit protocol
(NanoTemper Technologies). Hundred nanomolar of labelled enzyme were incu-
bated for 10 min at room temperature with 15d-PGJ2 at concentrations ranging
between 0.0038 and 125 µM (1:1 serial dilution). Microscale thermophoresis (MST)
experiments were performed at 20% of LED power and 40% of MST power with a
Monolith NT.115 (NanoTemper Technologies). Data analysis was performed using
the MO.control software (NanoTemper Technologies), ﬁtting the auto-normalised
data in manual mode. KD values were obtained by ﬁtting with dose-response
equations implemented in the MO.control software.
AlloSigMA analyses. AlloSigMA is a structure-based statistical mechanical model
tool which estimates the per-residue allosteric free energies (Δgi) associated with an
effector binding. Particularly, Δgi > 0 and Δgi < 0 correspond to increased and
decreased free energies associated to changes in stability due to allosteric signalling.
More precisely, these values quantify variations in conﬁgurational work exerted on
a speciﬁc residue, as a consequence of changes in the measured conﬁgurational
ensemble upon ligand binding (by normal mode analysis). The ligand binding
process is simulated in this framework by rigidifying (‘perturbing’) the residues
involved in the binding. The free energy variation associated with such perturba-
tion is approximated by a summation over the normal modes45. AlloSigMA ana-
lyses were carried out after identifying putative 15d-PGJ2 binding sites around the
two reactive cysteine residues C423 and C522 using SwissDock69. The docking of
15d-PGJ2 (ZINC05972962) was performed in accurate mode on the apoprotein
crystal structure solved in this study, centring the docking region of interest on the
Chain A sulphur atoms of C423 and C522, and allowing 3 Å side chains ﬂexibility.
The poses were further considered only when the ΔG obtained was lower than −5
kcal mol−1. Once the binding sites were deﬁned, the per-residue allosteric free
energy (Δgi) calculations were carried out using the AlloSigMA web-server70,
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perturbing the putative C423 and C522 binding sites (in isolation and together).
The results were presented in graphics coloured in red and blue scales to indicate,
respectively, stabilised and destabilised residues.
Statistics and reproducibility. The ESI-MS experiments, HPLC puriﬁcations, UV
and CD analyses, IC50 values measurements, STD-NMR experiments, MST ana-
lyses, and enzymatic activity measurements were carried out in at least three
biological replicates. The statistical signiﬁcance for the enzymatic activity experi-
ments was obtained by comparing the enzymatic rates with one-tailed homo-
scedastic t-test and reported in plots as average ± SEM. The statistical signiﬁcance
was reported as follows: *0.05 < p ≤ 0.005, **0.005 < p ≤ 0.0005, ***p < 0.0005.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Atomic coordinates for the X-ray crystallographic structures of hsEH CTD and hsEH
CTD-15d-PGJ2 complex are deposited in the Protein Data Bank under the accession
codes 6I5E (apo) and 6I5G (complex). All relevant data within the manuscript are
available for review or discussion by interested parties. Additional data are included as
Supplementary Information. If necessary, we can facilitate experiments planned by other
parties that are related to the results of our study. There are no large datasets and
accession codes that have contributed to the information in this paper. All relevant data
supporting the ﬁndings of this study are available from the authors upon reasonable
request.
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